Compound Radar

Becton, Dickinson and Company (BDX) Stock Analysis

Price $195.03
Market cap $53.12B
Next earnings Nov 5, 2026
Entry status Wait $158.59–$168.39

Last updated Oct 27, 2026

Health Check

Last analyzed Oct 23, 2026

63
63/100 Good Quality
  • Financial Health 55
  • Profitability 60
  • Business Quality 65
  • Balance Sheet 55
  • Cash Flow 80

Why this rating?

Health 63/100 — Good Quality

Strongest Cash Flow 80/100
Softest Balance Sheet 55/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Becton, Dickinson and Company (BDX) is a Medical Instruments & Supplies company in the Healthcare sector. Compound Radar rates Becton, Dickinson and Company 63/100 (Good Quality) due to solid business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality Moderate
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 45.36
  • Forward P/E 14.66
  • PEG 1.11
  • EV/Revenue 3.1

Profitability

  • Revenue Growth 5.4%
  • Gross Margin 46.9%
  • Operating Margin 15.7%
  • Net Margin 4.2%
  • ROE 6.6%

Financial strength

  • Cash $709.00M
  • Debt $16.81B
  • Net Cash $-16.10B
  • Free Cash Flow $2.67B
  • Current Ratio 0.87

Similar companies

Peers in Medical Instruments & Supplies, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Instruments & Supplies →

FAQ

How Compound Radar scores and tracks Becton, Dickinson and Company (BDX).

View Methodology & FAQ →